Sulfasalazine-induced Sweet's syndrome

Enhanced heterogeneous catalytic ozonation of pharmaceutical pollutants using a novel nanostructure of iron-based mineral prepared via plasma technology: A comparative study

Plasma-treated goethite nanoparticles with high surface area and improved density of surface hydroxyl groups were synthesized from natural goethite (NG) using Argon (PTG-Ar) and Nitrogen (PTG-N₂) as plasma environment to enhance the performance of heterogeneous catalytic ozonation process. Synthesized samples were characterized by FESEM, EDX, TEM, XRD, XPS, BET-BJH, FTIR, AAS and pH_PZC. Results indicated a significantly different morphology for the prepared samples with negligible change in crystal structure. Furthermore, the catalytic activity and synergy factor of the NG and PTG nanocatalysts were evaluated for degradation and mineralization of Sulfasalazine antibiotic (SSZ) as an environmental hazardous contaminant. The highest removal efficiency was achieved 96.05 % under the optimal operating conditions. The kinetic study confirmed the pseudo-first-order reaction for the degradation process. Moreover, the dissolved ozone concentration and effect of organic and inorganic salts were studied in order to assess the reactive oxidant species (ROSs) and catalyst active sites in the process. The mechanism investigation showed the catalytic ozonation of SSZ was mainly performed by successive attacks of hydroxyl radicals (•OH), superoxide radicals (O₂^-) and direct ozone molecules. Environmentally-friendly modification of the NG, negligible iron leaching, successive reusability and superior catalytic activity are the major benefits of the PTG nanoparticles.

Insights Into the Pathogenesis of Sweet's Syndrome

Sweet's syndrome, also known as Acute Febrile Neutrophilic Dermatosis, is a rare inflammatory condition. It is considered to be the prototype disease of neutrophilic dermatoses, and presents with acute onset dermal neutrophilic lesions, leukocytosis, and pyrexia. Several variants have been described both clinically and histopathologically. Classifications include classic Sweet's syndrome, malignancy associated, and drug induced. The cellular and molecular mechanisms involved in Sweet's syndrome have been difficult to elucidate due to the large variety of conditions leading to a common clinical presentation. The exact pathogenesis of Sweet's syndrome is unclear; however, new discoveries have shed light on the role of inflammatory signaling, disease induction, and relationship with malignancy. These findings include an improved understanding of inflammasome activation, malignant transformation into dermal infiltrating neutrophils, and genetic contributions. Continued investigations into effective treatments and targeted therapy will benefit patients and improve our molecular understanding of inflammatory diseases, including Sweet's syndrome.

Efficacy and safety of stellate ganglion block in chronic ulcerative colitis

AIM

To investigate the efficacy and safety of stellate ganglion block for the treatment of patients with chronic ulcerative colitis.

METHODS

A total of 120 randomly selected patients with chronic ulcerative colitis treated in Cangzhou Central Hospital from January 2014 to January 2016 were included in this study. These patients were divided into two groups: control group (n = 30), patients received oral sulfasalazine treatment; experimental group (n = 90), patients received stellate ganglion block treatment. Clinical symptoms and disease activity in these two groups were compared before and after treatment using endoscopy. Blood was collected from patients on day 0, 10, 20 and 30 after treatment. Enzyme-linked immunosorbent assay was performed to determine interleukin-8 (IL-8) level. The changes in IL-8 level post-treatment in the two groups were compared using repeated measures analysis of variance.

RESULTS

After treatment, clinical symptoms and disease activity were shown to be alleviated by endoscopy in both the control and experimental groups. However, patients in the control group did not have obvious abdominal pain relief. In addition, the degree of pain relief in the experimental group was statistically better than that in the control group (P < 0.05). Ten days after treatment, IL-8 level was found to be significantly lower in the experimental group than in the control group, and the difference was statistically significant (P < 0.05). In addition, adverse events were significantly higher in the control group than in the experimental group, and the difference was statistically significant (χ² = 33.215, P = 0.000).

CONCLUSION

The application of stellate ganglion block effectively improves treatment efficacy in chronic ulcerative colitis, relieves clinical symptoms in patients, and reduces the level of inflammatory factors. Furthermore, this approach also had a positive impact on the disease to a certain extent.